Progress in Biosimilar Monoclonal Antibody Development: the Infliximab Biosimilar Ct-P13 in the Treatment of Rheumatic Diseases
Authors:
- 25 February 2015
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 7 (2) , 73-87
Abstract
Biosimilars are biologic medical products whose active drug substance is made by a living organism or derived from it. The term is used to describe a subsequent version of an innovator biopharmaceutical product aiming at approval following patent expiry on the reference product. Biosimilars of monoclonal need to demonstrate similar but not identical quality of nonclinical and clinical attributes. Not all data of the originator product need to be recapitulated, as large numbers of patient-years of exposure data are already available. Thus, biosimilar development is largely based on the safety profiles of the originator product. The evaluation of biosimilarity includes immunogenicity attributed risks. CT-P13 (Remsima™/Inflectra™, Celltrion/Hospira), a biosimilar of the innovator drug infliximab (INF), was the first approved complex biosimilar monoclonal antibody in the EU, within the framework of WHO, EMA and US FDA biosimilar guidelines. CT-P13 has shown analytical and nonclinical features highly similar t...Keywords
Funding Information
- Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma
- Janssen, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB
This publication has 40 references indexed in Scilit:
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2012
- Biosimilars of Biological Drug TherapiesDrugs, 2011
- Biosimilars: The debate continuesArthritis & Rheumatism, 2011
- Biosimilars: a regulatory perspective from AmericaArthritis Research & Therapy, 2011
- Clinical Pharmacokinetics and Use??of??InfliximabClinical Pharmacokinetics, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- InfliximabDrugs, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004